NCT02351739 - Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

April 30, 2018

Conditions

Metastatic Urothelial Carcinoma

Interventions

DRUG

pembrolizumab

DRUG

ACP-196 in combination with pembrolizumab

Trial Locations (7)

University of Chicago, Chicago

University of Michigan, Ann Arbor

Durham

James Cancer Hospital, Columbus

Oregon Health and Science University, Portland

University of Pittsburgh, Pittsburgh

Carolina Urologic Research Center, Myrtle Beach